This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1998 Feb;16(2):803-4.

doi: 10.1200/JCO.1998.16.2.803.

Clinical benefit as a primary efficacy endpoint

E Ballatori, A Del Favero, F Roila

PMID: 9469377
DOI: 10.1200/JCO.1998.16.2.803

Comment

Clinical benefit as a primary efficacy endpoint

E Ballatori et al. J Clin Oncol. 1998 Feb.

. 1998 Feb;16(2):803-4.

doi: 10.1200/JCO.1998.16.2.803.

Authors

E Ballatori, A Del Favero, F Roila

PMID: 9469377
DOI: 10.1200/JCO.1998.16.2.803

No abstract available

PubMed Disclaimer

Comment on

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Burris HA 3rd, et al. J Clin Oncol. 1997 Jun;15(6):2403-13. doi: 10.1200/JCO.1997.15.6.2403. J Clin Oncol. 1997. PMID: 9196156 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information